FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to the use of a population of encapsulated pancreatic endocrine progenitor cells in the manufacture of a drug to reduce the blood glucose level in a patient, where pancreatic endocrine progenitor cells differentiate in vitro from cells, expressing markers characteristic of the pancreatic endoderm lineage in a medium with the addition of a factor capable of inhibiting BMP, and the TGF-beta receptor I kinase inhibitor, and where pancreatic endocrine progenitor cells express NGN3, NKX6.1, NeuroD, ISL1, PDX1, PAX4, NKX2.2, PAX6 or ARX.
EFFECT: above solution allows the use of a population of encapsulated pancreatic endocrine progenitor cells in the manufacture of a drug to reduce the blood glucose level in a patient.
9 cl, 3 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | 2023 |
|
RU2836628C1 |
| DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | 2018 |
|
RU2782271C2 |
| DIFFERENTIATION OF HUMAN EMBRYO STEM CELLS | 2011 |
|
RU2587634C2 |
| DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | 2022 |
|
RU2805433C1 |
| METHODS OF PURIFYING CELLS, DERIVED FROM PLURIPOTENT STEM CELLS | 2011 |
|
RU2607380C2 |
| DIFFERENTIATION OF HUMAN EMBRYO STEM CELLS | 2011 |
|
RU2663339C1 |
| METHODS FOR PURIFYING CELLS DERIVED FROM PLURIPOTENT STEM CELLS | 2011 |
|
RU2702198C2 |
| METHOD FOR OBTAINING PANCREATIC ENDOCRINE CELLS (VERSIONS) AND METHOD FOR INCREASING OUTPUT OF BETA CELLS | 2013 |
|
RU2684215C2 |
| CELL COMPOSITIONS DERIVED FROM DEDIFFERENTIATED REPROGRAMMED CELLS | 2014 |
|
RU2675928C2 |
| METHODS OF PRODUCING CELLS OF DEFINITIVE AND PANCREATIC ENDODERM | 2013 |
|
RU2668814C2 |
